MovDisordV3, Main, Exploration, bibRecord, 000B14

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease

Identifieur interne : 000B14 ( Main/Exploration ); précédent : 000B13; suivant : 000B15

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease

Auteurs : Yoshikuni Mizuno [Japon] ; Tomoyoshi Kondo [Japon]

Source :

Movement Disorders [ 0885-3185 ] ; 2013.

RBID : PMC:3842830

Descripteurs français

Wicri :
- geographic : Japon.

English descriptors

KwdEn :
- Adenosine A2 Receptor Antagonists (therapeutic use), Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Japan, Male, Middle Aged, Parkinson Disease (drug therapy), Purines (therapeutic use), Retrospective Studies, Treatment Outcome.
MESH :
- chemical , therapeutic use : Adenosine A2 Receptor Antagonists, Purines.
- geographic : Japan.
- drug therapy : Parkinson Disease.
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome.

Abstract

BackgroundWe evaluated the efficacy and safety of istradefylline, a selective adenosine A_2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson’s disease patients with motor complications in Japan.

MethodsA total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.

ResultsThe change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, P = .003) and istradefylline 40 mg/day (−0.96 hours, P = .003) groups compared with the placebo group (−0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).

ConclusionsIstradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842830

DOI: 10.1002/mds.25418
PubMed: 23483627
PubMed Central: 3842830

Affiliations:

Japon

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adenosine A<sub>2A</sub>
 receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Kitasato University School of Medicine</institution>
<addr-line>Kanagawa, Japan</addr-line>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Kanagawa</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Rehabilitation Hananoie Hospital</institution>
<addr-line>Tochigi, Japan</addr-line>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Tochigi</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">23483627</idno>
<idno type="pmc">3842830</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842830</idno>
<idno type="RBID">PMC:3842830</idno>
<idno type="doi">10.1002/mds.25418</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000010</idno>
<idno type="wicri:Area/Pmc/Curation">000010</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000140</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000994</idno>
<idno type="wicri:Area/PubMed/Curation">000994</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B27</idno>
<idno type="wicri:Area/Ncbi/Merge">003A87</idno>
<idno type="wicri:Area/Ncbi/Curation">003A87</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003A87</idno>
<idno type="wicri:Area/Main/Merge">000B14</idno>
<idno type="wicri:Area/Main/Curation">000B14</idno>
<idno type="wicri:Area/Main/Exploration">000B14</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Adenosine A<sub>2A</sub>
 receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Kitasato University School of Medicine</institution>
<addr-line>Kanagawa, Japan</addr-line>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Kanagawa</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Rehabilitation Hananoie Hospital</institution>
<addr-line>Tochigi, Japan</addr-line>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Tochigi</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement Disorders</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine A2 Receptor Antagonists (therapeutic use)</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Japan</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Purines (therapeutic use)</term>
<term>Retrospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine A2 Receptor Antagonists</term>
<term>Purines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Japan</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Retrospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Japon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><bold>Background</bold>
We evaluated the efficacy and safety of istradefylline, a selective adenosine A<sub>2A</sub>
 receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson’s disease patients with motor complications in Japan.</p>
<p><bold>Methods</bold>
A total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.</p>
<p><bold>Results</bold>
The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, <italic>P</italic>
 = .003) and istradefylline 40 mg/day (−0.96 hours, <italic>P</italic>
 = .003) groups compared with the placebo group (−0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).</p>
<p><bold>Conclusions</bold>
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Rajput, Ah" uniqKey="Rajput A">AH Rajput</name>
</author>
<author><name sortKey="Fenton, Me" uniqKey="Fenton M">ME Fenton</name>
</author>
<author><name sortKey="Birdi, S" uniqKey="Birdi S">S Birdi</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Olanow, Cw" uniqKey="Olanow C">CW Olanow</name>
</author>
<author><name sortKey="Watts, Rl" uniqKey="Watts R">RL Watts</name>
</author>
<author><name sortKey="Koller, Wc" uniqKey="Koller W">WC Koller</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Mori, A" uniqKey="Mori A">A Mori</name>
</author>
<author><name sortKey="Shindou, T" uniqKey="Shindou T">T Shindou</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Jenner, P" uniqKey="Jenner P">P Jenner</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Park, A" uniqKey="Park A">A Park</name>
</author>
<author><name sortKey="Stacy, M" uniqKey="Stacy M">M Stacy</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Shiozaki, S" uniqKey="Shiozaki S">S Shiozaki</name>
</author>
<author><name sortKey="Ichikawa, S" uniqKey="Ichikawa S">S Ichikawa</name>
</author>
<author><name sortKey="Nakamura, J" uniqKey="Nakamura J">J Nakamura</name>
</author>
<author><name sortKey="Kitamura, S" uniqKey="Kitamura S">S Kitamura</name>
</author>
<author><name sortKey="Yamada, K" uniqKey="Yamada K">K Yamada</name>
</author>
<author><name sortKey="Kuwana, Y" uniqKey="Kuwana Y">Y Kuwana</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Kanda, T" uniqKey="Kanda T">T Kanda</name>
</author>
<author><name sortKey="Jackson, Mj" uniqKey="Jackson M">MJ Jackson</name>
</author>
<author><name sortKey="Smith, La" uniqKey="Smith L">LA Smith</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Grondin, R" uniqKey="Grondin R">R Grondin</name>
</author>
<author><name sortKey="Bedard, Pj" uniqKey="Bedard P">PJ Bedard</name>
</author>
<author><name sortKey="Hadj Tahar, A" uniqKey="Hadj Tahar A">A Hadj Tahar</name>
</author>
<author><name sortKey="Gregoire, L" uniqKey="Gregoire L">L Gregoire</name>
</author>
<author><name sortKey="Mori, A" uniqKey="Mori A">A Mori</name>
</author>
<author><name sortKey="Kase, H" uniqKey="Kase H">H Kase</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Kanda, T" uniqKey="Kanda T">T Kanda</name>
</author>
<author><name sortKey="Jackson, Mj" uniqKey="Jackson M">MJ Jackson</name>
</author>
<author><name sortKey="Smith, La" uniqKey="Smith L">LA Smith</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Hauser, Ra" uniqKey="Hauser R">RA Hauser</name>
</author>
<author><name sortKey="Hubble, Jp" uniqKey="Hubble J">JP Hubble</name>
</author>
<author><name sortKey="Truong, Dd" uniqKey="Truong D">DD Truong</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Bara Jimenez, W" uniqKey="Bara Jimenez W">W Bara-Jimenez</name>
</author>
<author><name sortKey="Sherzai, A" uniqKey="Sherzai A">A Sherzai</name>
</author>
<author><name sortKey="Dimitrova, T" uniqKey="Dimitrova T">T Dimitrova</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lewitt, Pa" uniqKey="Lewitt P">PA LeWitt</name>
</author>
<author><name sortKey="Guttman, M" uniqKey="Guttman M">M Guttman</name>
</author>
<author><name sortKey="Tetrud, Jw" uniqKey="Tetrud J">JW Tetrud</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Stacy, M" uniqKey="Stacy M">M Stacy</name>
</author>
<author><name sortKey="Silver, D" uniqKey="Silver D">D Silver</name>
</author>
<author><name sortKey="Mendis, T" uniqKey="Mendis T">T Mendis</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Hauser, Ra" uniqKey="Hauser R">RA Hauser</name>
</author>
<author><name sortKey="Shulman, Lm" uniqKey="Shulman L">LM Shulman</name>
</author>
<author><name sortKey="Trugman, Jm" uniqKey="Trugman J">JM Trugman</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Pourcher, E" uniqKey="Pourcher E">E Pourcher</name>
</author>
<author><name sortKey="Fernandez, Hh" uniqKey="Fernandez H">HH Fernandez</name>
</author>
<author><name sortKey="Stacy, M" uniqKey="Stacy M">M Stacy</name>
</author>
<author><name sortKey="Mori, A" uniqKey="Mori A">A Mori</name>
</author>
<author><name sortKey="Ballerini, R" uniqKey="Ballerini R">R Ballerini</name>
</author>
<author><name sortKey="Chaikin, P" uniqKey="Chaikin P">P Chaikin</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Mizuno, Y" uniqKey="Mizuno Y">Y Mizuno</name>
</author>
<author><name sortKey="Hasegawa, K" uniqKey="Hasegawa K">K Hasegawa</name>
</author>
<author><name sortKey="Kondo, T" uniqKey="Kondo T">T Kondo</name>
</author>
<author><name sortKey="Kuno, S" uniqKey="Kuno S">S Kuno</name>
</author>
<author><name sortKey="Yamamoto, M" uniqKey="Yamamoto M">M Yamamoto</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Hughes, Aj" uniqKey="Hughes A">AJ Hughes</name>
</author>
<author><name sortKey="Daniel, Se" uniqKey="Daniel S">SE Daniel</name>
</author>
<author><name sortKey="Kilford, L" uniqKey="Kilford L">L Kilford</name>
</author>
<author><name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Ochi, M" uniqKey="Ochi M">M Ochi</name>
</author>
<author><name sortKey="Koga, K" uniqKey="Koga K">K Koga</name>
</author>
<author><name sortKey="Kurokawa, M" uniqKey="Kurokawa M">M Kurokawa</name>
</author>
<author><name sortKey="Kase, H" uniqKey="Kase H">H Kase</name>
</author>
<author><name sortKey="Nakamura, J" uniqKey="Nakamura J">J Nakamura</name>
</author>
<author><name sortKey="Kuwana, Y" uniqKey="Kuwana Y">Y Kuwana</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Brooks, Dj" uniqKey="Brooks D">DJ Brooks</name>
</author>
<author><name sortKey="Doder, M" uniqKey="Doder M">M Doder</name>
</author>
<author><name sortKey="Osman, S" uniqKey="Osman S">S Osman</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
</list>
<tree><country name="Japon"><noRegion><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
</noRegion>
<name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B14 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B14 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3842830
   |texte=   Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23483627" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.